PepVax Announces Completion of Efficacy Study with Key Pre-Clinical Data to Validate PVX-009, Addition to its Advisory Board and Other Updates

BETHESDA, Md., Jan. 5, 2018 /PRNewswire/ -- PepVax, Inc., an early-stage biotechnology company, announced today that it has successfully completed the efficacy study for its lead candidate, PVX-009. The Company is harnessing the power of the immune system to target a specific protein,...